Furthermore, many questions remain, and additional studies are needed to optimize these therapeutic strategies in the clinical setting; however, recent results are encouraging and demonstrate the potential to adequately treat patients with KRAS-mutant NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.